ERBB2 and breast cancer: This effect was most pronounced in HER2+ BC, as 83.7% (41/49) of patients with absent extracranial metastases showed neurological symptoms at diagnosis of BM compared to 68.5% (124/181) of patients with concurrent BM and extracranial disease (p = 0.036; chi-square test; Supplementary Table 2).